GVHD-derived plasma as a priming strategy of mesenchymal stem cells

BACKGROUND: Mesenchymal stem cell (MSC) therapy is an important alternative for GVHD treatment, but a third of patients fail to respond to such therapy. Therefore, strategies to enhance the immunosuppressive potential of MSCs constitute an active area of investigation. Here, we proposed an innovativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva-Carvalho, Amandda Évelin, Rodrigues, Leane Perim, Schiavinato, Josiane Lilian, Alborghetti, Marcos Rodrigo, Bettarello, Gustavo, Simões, Belinda Pinto, Neves, Francisco de Assis Rocha, Panepucci, Rodrigo Alexandre, de Carvalho, Juliana Lott, Saldanha-Araujo, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164240/
https://www.ncbi.nlm.nih.gov/pubmed/32299501
http://dx.doi.org/10.1186/s13287-020-01659-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164240/
https://www.ncbi.nlm.nih.gov/pubmed/32299501
http://dx.doi.org/10.1186/s13287-020-01659-x

Ejemplares similares